Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.46 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2913941 | 0.82 | PDE10A (0.61) | PDE10ACYP1A2CYSLTR1CYSLTR2CYP3A4 | |
| SCHEMBL9688391 | 0.81 | PDE10A (0.50) | PDE10ACYP1A2CYSLTR1CYSLTR2CYP3A4 | |
| SCHEMBL5547093 | 0.81 | HDAC1 (0.55) | CYP1A2CYSLTR1CYSLTR2HDAC1HDAC2 | |
| SCHEMBL29858122 | 0.80 | HTT (0.55) | CYP1A2HDAC1HDAC2ALDH1A1 | |
| SCHEMBL19385987 | 0.80 | HTT (0.55) | CYP1A2HDAC1HDAC2ALDH1A1 | |
| SCHEMBL296473 | 0.79 | PDE10A (0.50) | PDE10ACYP1A2CYSLTR1CYSLTR2CYP3A4 | |
| SCHEMBL6798820 | 0.78 | CYSLTR2 (0.53) | PDE10ACYP1A2CYSLTR1CYSLTR2CYP3A4 | |
| SCHEMBL22493232 | 0.77 | PDE10A (0.47) | PDE10ACYP1A2CYSLTR1CYSLTR2CYP3A4 | |
| SCHEMBL8188980 | 0.77 | CYP1A2 (0.46) | PDE10ACYP1A2CYSLTR1CYSLTR2HDAC1 | |
| SCHEMBL2334595 | 0.76 | CYSLTR2 (0.52) | PDE10ACYP1A2CYSLTR1CYSLTR2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180222905-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-08-09 | — | — | US | disclosed |
| US-9938269-B2 | Inhibitor compounds of phosphodiesterase type 10A | ABBVIE INC. (US) | 2018-04-10 | — | — | US | disclosed |
| EP-2726479-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co KG (DE) | 2014-05-07 | — | — | EP | disclosed |
| WO-2013000994-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBOTT GMBH & CO. KG (DE) | 2013-01-03 | — | — | WO | disclosed |
| US-20130005705-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBOTT LABORATORIES (US) | 2013-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005705-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE2A, PDE4A, PDE5A | PDE10A 13/4885CYP1A2 714/4885CYSLTR1 2669/4885 |
| US-20180222905-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE2A, PDE4A, PDE5A | PDE10A 13/4885CYP1A2 714/4885CYSLTR1 2669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.